Topical Janus kinase-signal transducers and activators of transcription inhibitor tofacitinib is effective in reducing nonatopic dermatitis chronic itch: A case series

Abstract

To the Editor: Chronic and refractory pruritus is a highly common complaint among patients with dermatologic conditions and remains difficult to treat with current drug therapies. In particular, there is an unmet need for potent topical antipruritics. The Janus kinase (JAK) 1/3 inhibitor tofacitinib significantly decreases itch-associated interleukin 22, 23, and 31 levels and may rescue inhibitory itch mechanisms via increased peptidergic epidermal nerve fiber density, making it a good candidate for the treatment of chronic and refractory pruritus.